TOCILIZUMAB is a Schedule H drug.


Mepolizumab is a monoclonal antibody that affects the actions of the body’s immune system. Mepolizumab is used together with other medicines to help control severe asthma in adults and children who are at least 12 years old. Mepolizumab is an interleukin-5 antagonist. It blocks the binding of interleukin-5 (a molecule produced by immune cells) to the eosinophils and thereby reduces the production, maturation, and circulation of the eosinophils.


Canakinumab is a monoclonal antibody that blocks certain proteins in the body that can affect inflammation and other immune responses. This medication is an interleukin-1 beta-blocker, prescribed for auto-inflammatory diseases known as cryopyrin-associated periodic syndrome (CAPS). It decreases interleukin-1 beta’s activity. Canakinumab is used to treat certain types of periodic fever syndromes, sometimes called auto-inflammatory syndromes. It is also approved to treat systemic juvenile idiopathic arthritis (SJIA) in children two years and older.